A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

The map was developed by using single-cell RNA sequencing to analyze 1.4 million plasma and immune cells in bone marrow from over 300 patients.

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma ...

Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the ...

On average, we wait 867 days (approximately 2.5 years) for public coverage of certain blood cancer treatments. Fifteen other ...

In a groundbreaking development, First Ascent Biomedical unveils a compelling narrative of resilience and innovation through ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Bone and blood cancers impact millions of people around the world. These are different types of cancers that affect the blood ...

Biotech Amgen will grow its oncology treatment options with the acquistion of UK-based Dark Blue Therapeutics.